Analyst Ritu Baral of TD Cowen maintained a Buy rating on Akero Therapeutics, retaining the price target of $76.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ritu Baral has given her Buy rating due to a combination of factors related to Akero Therapeutics’ ongoing clinical trials and financial position. The company’s SYNCHRONY program, which includes three Phase 3 trials, is progressing well. These trials are designed to evaluate the efficacy and safety of efruxifermin (EFX) across different stages of MASH, with key data expected in the coming years. The successful completion and positive outcomes of these trials could potentially lead to accelerated approval, enhancing the company’s market position.
Additionally, Akero Therapeutics has a strong financial foundation with $1.1 billion in cash, providing an operational runway through 2028. Despite reporting a net loss in the second quarter of 2025, the company’s cash reserves and controlled expenses in research and development and general administrative areas suggest a stable financial outlook. These factors collectively support Ritu Baral’s optimistic view and her Buy rating on the stock.
In another report released on August 6, Morgan Stanley also maintained a Buy rating on the stock with a $84.00 price target.